Comparing Alzheimer's, Lewy body dementia and Parkinson's disease through tests and scans
Studies how Alzheimer's, Lewy body dementia and Parkinson's look in adults with each disease.
Plain-language title generated from the registry record
Registry title: Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Key facts
- Where
- Columbus, United StatesSee the site
Where in United States
- The Ohio State UniversityColumbus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Douglas Scharre
- Trial code
- NCT03019757
- Record updated
- 15 October 2026
- Original description
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.Read full original descriptionShow less
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Inclusion: Subjects must meet the standard clinical criteria of the syndromes of interest; All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10; Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment; Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week; Subjects must have visual and auditory acuity adequate for testing.
Exclusion: Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial; Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment; active medical disorder that could preclude participation in this protocol; severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan); Women who are pregnant or are breast feeding; Subjects in whom English is not the 1st language; Subjects with educational level less than 12 years.